Loading…
ABVX
Abivax S.A.
NASDAQ· Healthcare· Biotechnology· CUSIP 00370M103
$90.23-3.49%Price as of Oct 23, 00:49 UTC · updated once a day, after the close
At a glance
Abivax S.A. (ABVX) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Paris, France and has 98 employees. The company is worth $7.87B. Revenue was €0 in fiscal 2025. It reported a net loss of €336.1M. The share price is 39.4% below its 52-week high of $148.83. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Ken Griffin (Citadel Advisors), at $191.67M. In that quarter, 2 of them opened or added to the position and 2 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $7.87B
- P/E
- —
- Forward P/E
- —
- P/B
- 17.5x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- -$6.08
- ROE
- -252.35%
- Profit margin
- 0.00%
- Revenue growth
- -6.80%
- Beta
- -0.23
- 52-week high
- $148.83
- 52-week low
- $69.81
History
Year by year, from the annual reports; dividends from the payments themselves.
Revenue, debt and profit are in EUR, the currency the company reports in — not converted to dollars. Dividends are in dollars.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▲ +857.9% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 3 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Year-end price | $134.85 | $7.32 | $10.70 | |
| EPS | -€4.83 | -€2.78 | -€3.43 | |
| ROE | -75.37% | -73.84% | -434.26% | -75.37% |
This company reports in EUR, and the stock trades in dollars. P/E, P/S, P/B and payout would divide dollars by EUR, so they are not shown; EPS is in EUR. Margin, ROE and dividend yield do not depend on the currency.
Median of the years shown; P/E years above 200x are left out.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TGTXTg Therapeutics Inc | $53.16 | 19.3x | 12.5x | 0.00% | 100.28% | $8.14B |
| ATRAptargroup Inc | $128.10 | 23.1x | 3.1x | 1.50% | 13.46% | $8.14B |
| AXSMAxsome Therapeutics, Inc. | $156.07 | — | 98.0x | 0.00% | -245.10% | $8.18B |
| ARWRArrowhead Pharmaceuticals Inc | $58.36 |
About the company
- 98
- Paris, France